Original Agenda
We are actively working with our speakers to confirm their availability for the virtual event. Initial response from our speakers has been very positive, and we are optimistic we will have the new programs ready to share here soon.

Advancing Bispecifics and Combination Therapy to the Clinic track banner

T cell engagement continues to be a focus for bispecific investigators, many of whom are looking for superiority in terms of low cytokine release, improved potency and specificity, and longer half-life. After initial excitement with the checkpoint inhibitors, it is clear that bispecifics and complementary combinations are the way forward. Investigators are working on novel approaches for activating the immune response, developments with anti-CD47, and bispecifics for haemophilia. Some products are entering the clinic with promising results.

Wednesday, 11 November

07:45 Registration and Morning Coffee

BISPECIFICS WITH CHECKPOINT INHIBITORS TOGETHER AND IN COMBINATION

08:30

Chairperson's Opening Remarks

Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
08:35 PD1-X: Targeting PD-1 with Bispecific Agents
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Pharma Research & Early Development, Roche Innovation Center Zurich

Targeting of the PD-1/PD-L1 axis with monoclonal antibodies is the basis for cancer immunotherapy and has transformed the therapy of various cancers. However, many patients still do not respond to cancer immunotherapy and relapse after treatment. We have generated bispecific PD-1/TIM-3 and PD-1/LAG-3 checkpoint inhibitory antibodies with superior properties over PD-1 monotherapy as well as a novel PD-1 targeted PD1-IL2v immunocytokine to specifically target PD-1+ T cells. The design and preclinical properties of these PD1-X molecules will be discussed in depth during this presentation.

09:05

MGD019, a PD-1 x CTLA-4 Bispecific DART® Protein, with Optimal Dual Checkpoint Blockade and Favorable Tolerability

Alexey Berezhnoy, PhD, Scientist II, MacroGenics, Inc.

We developed MGD019, a bispecific DART protein designed to maintain full blockade of both PD-1 and CTLA-4, while limiting Fc-mediated effector function. MGD019 demonstrated increased CTLA-4 blockade on dual-expressing cells that recapitulate tumor-infiltrating T lymphocytes, and T cell co-activation in vitro at least as potent as combination of ipilimumab and nivolumab, although with a somewhat different pattern. MGD019 was well tolerated in cynomolgus monkeys, while providing evidence of CTLA-4 blockade. Preclinical pharmacology and additional information relevant to a Phase 1 clinical trial will be discussed.

09:35 Clinical Data from a NIVO/IPI Trial for Metastatic Melanoma and Kidney Cancer
John Wagstaff, MD, Consultant, Medical Oncology, South West Wales Cancer Institute
Maria Pajuelo, CSO, FairJourney Biologics SA

FairJourney Biologics is a leading antibody discovery, engineering, characterisation and production company. Our immune libraries, Human Fab and llama VHH naïve libraries consistently yielded excellent panels of antibodies against difficult targets. We continue the journey to increase our capabilities to be able to offer you antibody based solutions to all type of problems.

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

T CELL ENGAGEMENT

11:15 KEYNOTE PRESENTATION:

Next-Generation T Cell Engagers

Paul Parren, PhD, Executive Vice President & Head, Lava Therapeutics

The development of next generation bispecific T cell engagers (bsTCEs) with a widened therapeutic window characterized by high potency and high tumor selectivity has strong potential. Lava Therapeutics’ platform is based on the selective recruitment of Vγ9Vδ2 T cells for eradicating tumor cells. This γδ T cell subset has been shown to display powerful anti-tumor immune effector activity with an ability to infiltrate human tumors in which its abundance has been shown to positively correlate with patient survival. This presentation will discuss a novel class of bsTCEs designed to engage Vγ9Vδ2-T cells for the development of efficacious and safe cancer immunotherapies.

11:45 BiTE® Antibody Constructs for the Treatment of Cancer
Roman Kischel, MD, Director, Research & Early Development Lead, Oncology, Amgen Research Munich GmbH

The presentation will discuss structure and mode of action of BiTE antibody constructs, provide an update on the development of the BiTE antibody platform, and showcase clinical data for a novel BiTE antibody construct targeting AML.

12:15 Triclonics™ ENGAGE: Trispecific Antibody Platform for the Discovery of Next-Generation T Cell Engagers
Pieter Fokko Van Loo, PhD, Director Oncology Immunology, Merus NV

Triclonics Engagers are multivalent molecules with three Fab arms that bind up to three different targets and are designed to have long half-life, stability and low immunogenicity. The presentation will highlight the novel features and therapeutic opportunities of the platform, and functional screening of thousands of Triclonics Engagers in T cell assays.

12:45 Sponsored Presentation (Opportunity Available)
13:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
14:15 Session Break

T CELL ENGAGEMENT (CONT.)

14:30

Chairperson's Remarks

Paul Parren, PhD, Executive Vice President & Head, Lava Therapeutics
14:35 Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.

This presentation will describe key preclinical data from Regeneron’s clinical stage T cell-redirecting bispecific programs (REGN1979, REGN4018, REGN5458), as well as status updates from the ongoing clinical trials. In addition, data from new combinatorial approaches being taken to enhance bispecific anti-tumor efficacy, focusing on costimulatory bispecifics, will be discussed.

15:05 Modulating the Immune System with Multi-Specific Antibodies for the Treatment of Cancer
Nathan D. Trinklein, PhD, CTO, TeneoBio Inc.

Tumor-targeted immune agonist antibodies increase the therapeutic index of cancer therapies.  Using NGS-based discovery with humanized rats, we created a large collection of fully human antibodies targeting a variety of tumor antigens and activating receptors on immune cells.  Our lead program, TNB-383B (BCMAxCD3) is currently in clinical studies for the treatment of multiple myeloma.  In addition to CD3 bispecific antibodies, immune-stimulatory platforms recently developed at Teneobio will also be discussed.

15:35 Refreshment Break in the Exhibit Hall with Poster Viewing

NOVEL APPROACHES ACTIVATING THE IMMUNE RESPONSE

16:15 Dual Agonist Bispecific Antibody Targeting CD137 and OX40 Mediates Anti-Tumour Immunity
Francisca Wollerton, PhD, Director, Antibody Engineering, F-star Biotechnology, Ltd.

 

This presentation will describe preclinical data on the potent anti-tumor activity of FS120, a first-in-class dual-agonist, tetravalent bispecific antibody targeting CD137 and OX40. FS120 delays tumor growth by improving the activation and proliferation of T cells.  FS120 can activate both CD4+ and CD8+ T cells in an FcγR-independent mechanism, therefore promoting focused immune stimulation. F-star’s proprietary mAb2™ technology platform will also be discussed. 

 

 

16:45 Translational Studies from Preclinical to the Clinic for a HER2/41BB Bispecific for Gastric Cancer
Shane A. Olwill, PhD, Senior Vice President, Head of Translational Science, Pieris Pharmaceuticals GmbH

PRS-343 is a first-in-class bispecific antibody-Anticalin fusion protein targeting HER2 and the costimulatory immune receptor 4-1BB on T cells. This presentation will describe the rational for tumor localized 4-1BB agonism with PRS-343 together with supporting preclinical and clinical data. PRS-343 is currently in early clinical testing where it has demonstrated a good safety profile and single agent efficacy.

17:15 Priming Neoantigen-Specific T Cells Using ATOR-4224, a Novel CD40xEpCAM bsAb Generated in the RUBY™ Format
Mattias Levin, PhD, Senior Scientist, Alligator Bioscience AB

ATOR-4224 is a novel tumor-targeted dendritic cell (DC) activator, acting as an endogenous neoantigen delivery vehicle to prime tumor-specific T cells. Simultaneous targeting of patient-specific tumor debris to DCs and DC activation leads to T cell priming, activation and induction of an anti-tumor response, with potential to turn cold tumors hot. ATOR-4224 is built in the RUBY format, a novel plug-and-play tetravalent bispecific format with favorable developability properties.

17:45 Networking Reception in the Exhibit Hall with Poster Viewing
18:45 Problem Solving Breakout Discussions*

*Topics to be announced.

19:45 End of Day

Thursday, 12 November

08:00 Registration and Morning Coffee

POTENTIAL OF TARGETING CD47/ANTI PD-L1 x IL-15 IgM

08:00

Chairperson's Remarks

Nicolas Fischer, PhD, CEO, Light Chain Bioscience
08:05 LockBody™: Optimised, Simplified, Tumour-Activated Bispecifics – CD47 and Beyond
Jonny Finlay, PhD, CEO, UltraHuman, Ltd.

Checkpoint inhibitors are mostly active only in the small subset of tumours where T cell immunity pre-exists. Molecules that safely enhance immunogenicity in the tumour are therefore highly desirable to optimise therapy. Bispecific immune engagers are ideal for this purpose, but their high potency and low-target specificity leads to low therapeutic index. We have developed LockBody™ technology to optimally overcome these historical bispecific limitations, maximising potency and therapeutic index.

08:35 CD47 Dual Targeting Enhances Safety and Pharmacokinetics
Nicolas Fischer, PhD, CEO, Light Chain Bioscience

Safe and selective blockade of the ubiquitously expressed immune checkpoint CD47 can be achieved using bispecific antibodies (bsAb) incorporating two arms with different affinities. This dual targeting concept has been validated in different preclinical models of human cancer and applied to different tumor associated antigens. This approach is now been explored in patients with a bsAb generated using our kappa-Lambda body platform.

09:05 IgA Antibody Therapy Further Enhanced by Targeting CD47
Jeanette H.W. Leusen, PhD, Associate Professor, Translational Immunology, Utrecht University

Polymorphonuclear neutrophils (PMN, or just neutrophils) can be effectively activated by antibodies of the IgA isotype to kill cancer cells. We collected evidence for killing of EGFR, HER2, GD2, and CD20 positive targets to be effectively killed by neutrophils by a process termed trogoptosis. Simultaneous blocking of CD47 or SIRPα as myeloid checkpoint inhibition molecule can even further enhance the killing by PMN and IgA, in vitro and in vivo.

09:35 Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15
Daniel S. Chen, MD, PhD, CMO, IGM Biosciences

Initial successes in cancer immunotherapy largely relied on therapeutics that inhibit a specific receptor wherever it exists. This can lead to anti-cancer immunity and autoimmunity, and consequent limitations in the clinical benefit. Novel approaches that leverage an increasing appreciation for immune biology, biophysics and advances in therapeutic engineering are likely to be important. These principles and a case study of an Anti-PD-L1 x IL-15 IgM therapeutic antibody will be presented. 

10:05 Sponsored Presentation (Opportunity Available)
10:35 Coffee Break in the Exhibit Hall with Poster Viewing

BISPECIFICS FOR HAEMOPHILIA: INNOVATIVE APPROACHES

11:15

New Factor VIII Function-Mimetic Bispecific Antibodies Engineered from Emicizumab for Further Improving the Treatment of Haemophilia A

Yuri Teranishi, Research Scientist, Discovery Research, Chugai Pharmaceutical Co., Ltd.

Emicizumab is a factor (F)VIII-function mimetic therapeutic antibody for treating persons with haemophilia A (PwHA). Currently, it plays a central role in treating PwHA, although there is some room for improvement in dosing frequency/volume and/or haemostatic activity to achieve non-haemophilic status. In this presentation, a novel antibody engineering technology to further improve the property of emicizumab will be presented.

11:45

Mim8: Development of a Next-Generation Factor VIII-Mimetic Bispecific Antibody

Jais R. Bjelke, PhD, Senior Scientist, Global Research, Novo Nordisk AS

A next-generation FVIII-mimetic bispecific antibody for treatment of Haemophilia A was developed based on the robust and versatile arm-exchange DuoBody® technology. The preclinical route from idea to antibody screening, engineering, and final selection of the development candidate, Mim8, and manufacturability aspects of using the arm-exchange technology will be presented. In vivo studies highlighting potency and efficacy of Mim8 in a rodent bleeding model will conclude the presentation.

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
13:15 Dessert Break in the Exhibit Hall with Poster Viewing
14:00 Close of Advancing Bispecifics and Combination Therapy to the Clinic
17:00 Dinner Short Course Registration
17:30 Recommended Dinner Short Course*
SC6: Engineering of Bispecific Antibodies and Multi-Specific Non-Antibody Scaffolds

*Separate registration required. See short course page for details.